

PROLIGHT'S RIGHTS ISSUE FULLY SUBSCRIBED

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Prolight Diagnostics AB (publ) ("Prolight" or the "Company") hereby announces the final outcome of the rights issue of shares, which the board of directors resolved on May 21, 2025, and later approved by an Extraordinary General Meeting on June 10, 2025 (the "Rights Issue"). The Rights Issue was fully subscribed whereas approximately 70.2 percent was subscribed with subscription rights and approximately 29.8 percent was subscribed without subscription rights. Through the Rights Issue, the Company will receive net proceeds of approximately SEK 100.3 million before issue costs and set-offs.

CEO Ulf Bladin comment on the outcome

"We would like to extend our sincere thanks to our shareholders for the strong support you have shown, and warmly welcome our new investors. Your commitment has enabled a cost-effective financing without the need for underwriters. The significant participation from our board, management, and employees, who together invested approx. SEK 10 million, as well as our instrument contract manufacturing partner, ITL, contributing approx. SEK 9.9 million, underscores the shared confidence in our strategy and future. The capital raised through this rights issue enables us to optimize, verify, and complete the development of our point-of-care system Psyros, finalize validated pilot production lines for both cartridges and instruments, accelerate business development efforts aimed at securing a commercial partnership and prepare for market access, initiate the clinical performance study and regulatory processes, as well as to build inventory ahead of commercial launch of Psyros in Europe", said Ulf Bladin, CEO at Prolight Diagnostics.

Preliminary outcome of the Rights Issue

The subscription period in the Rights Issue ended on June 30, 2025. The final outcome shows that 351 805 515 shares, corresponding to approximately 70.2 percent of the Rights Issue, have been subscribed for with subscription rights in the Rights Issue. In addition, applications have been received to subscribe for 149 686 965 shares without subscription rights, corresponding to approximately 29.8 percent of the Rights Issue. Thus, the final outcome shows that a total of 501,492,480 shares has been subscribed for in the Rights Issue, with and without subscription rights, corresponding to a subscription rate of 100 percent. The Rights Issue is thus fully subscribed.

Allocation of shares subscribed without subscription rights

Allotment of shares subscribed for without subscription rights has been made in accordance with the principles set out in the information document published by the Company on June 13, 2025, in connection with the Rights Issue. Notice of such allotment will be announced separately through a settlement note. Nominee-registered shareholders will receive notification of allotment in accordance with instructions from the respective nominee.

Trading in paid subscribed shares ("BTA")

The last day of trading in BTAs is expected to be July 16, 2025. Trading in the new shares subscribed for with and without subscription rights is expected to commence on Nordic SME Sweden on or around July 18, 2025.

Shares and share capital

Through the Rights Issue, the total number of shares in the Company will increase by 501,492,480 shares, from 702,089,478 shares to 1,203,581,958 shares, and the share capital will increase by SEK 50,149,248.00, from SEK 70,208,947.80 to SEK 120,358,195.80. This corresponds to a dilution effect of approximately 41.7 percent of the total number of shares and votes in the Company.

Advisors

Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

This information is information that Prolight Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-02 08:05 CEST.

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Important Information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade shares, warrants or other securities in Prolight. No action has been taken and no action will be taken to allow an offer to the public in any jurisdiction other than Sweden. This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 ("**Prospectus Regulation**"), and this press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Prolight. The information in this press release is only intended to describe the background to the exercise of the warrants and does not claim to be complete or exhaustive. No assurance shall be given with respect to the accuracy or completeness of the information in this press release.

The information in this press release may not be published, released or distributed, directly or indirectly, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require other actions than those following from Swedish law. Actions in violation of this instruction may constitute violations of applicable securities laws. No shares, warrants or other securities in Prolight have been registered, and no shares, warrants or other securities will be registered, under the then-applicable United States Securities Act of 1933 (the "**Securities Act**") or securities legislation in any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States except in accordance with an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or other jurisdiction in the United States.

The Company considers that it is engaged in activities worthy of protection under the Foreign Direct Investment Review Act (2023:560) (the "**FDI Act**"). In accordance with the FDI Act, the Company must inform prospective investors that the Company's activities may fall within the scope of the regulation and that the investment may be notifiable. If an investment is notifiable, it must be notified to the Swedish Inspectorate for Strategic Products (ISP) prior to its implementation. An investment may be notifiable if, after the investment is implemented, the investor, any member of its ownership structure or any person on whose behalf the investor is acting, holds voting rights equal to or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 per cent of the total number of votes in the Company. An administrative fine may be imposed on the investor if a notifiable investment is made before the ISP has either: (i) decided to leave the notification without action; or (ii) approved the investment. Each shareholder should consult an independent legal advisor regarding the potential application of the FDI Law in relation to the Rights Issue for the individual shareholder.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “**Order**”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “**relevant persons**”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Attachments

Prolight's rights issue fully subscribed